So the honest answer is that the comparison exists but the numbers are not public
The Batsis review answers this directly
Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, and Rosebraugh C
Recent FDA approvals have expanded the indication for semaglutide to include the reduction of major adverse cardiovascular events (MACE), such as heart attack, stroke, and cardiovascular death, in adults with established cardiovascular disease and obesity
TB-500 upregulates VEGF and actin-binding proteins to initiate new capillary formation, while BPC-157 stabilises and organises the resulting vascular networks through its endothelial repair and VEGFR2 signalling activity